{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:39:56Z","timestamp":1792172396758,"version":"4.4.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T00:00:00Z","timestamp":1689120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T00:00:00Z","timestamp":1689120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003141","name":"Consejo Nacional de Ciencia y Tecnolog\u00eda","doi-asserted-by":"publisher","award":["782280"],"award-info":[{"award-number":["782280"]}],"id":[{"id":"10.13039\/501100003141","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010096","name":"Secretar\u00eda de Educaci\u00f3n P\u00fablica","doi-asserted-by":"publisher","award":["511-6\/2020-8585"],"award-info":[{"award-number":["511-6\/2020-8585"]}],"id":[{"id":"10.13039\/100010096","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Pediatr"],"DOI":"10.1007\/s00431-023-05103-z","type":"journal-article","created":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T09:02:11Z","timestamp":1689152531000},"page":"4143-4152","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Model-informed precision dosing of antimicrobial drugs in pediatrics: experiences from a pilot scale program"],"prefix":"10.1007","volume":"182","author":[{"given":"Rodrigo","family":"Velarde-Salcedo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Fernando","family":"P\u00e9rez-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Socorro","family":"Rodr\u00edguez-B\u00e1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Javier","family":"Arriaga-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1040-8184","authenticated-orcid":false,"given":"Rosa del Carmen","family":"Mil\u00e1n-Segovia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4885-3745","authenticated-orcid":false,"given":"Silvia","family":"Romano-Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3962-8474","authenticated-orcid":false,"given":"Susanna Edith","family":"Medell\u00edn-Garibay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,12]]},"reference":[{"key":"5103_CR1","doi-asserted-by":"crossref","unstructured":"Dadgostar P (2019) Antimicrobial resistance: implications and costs. Infect Drug Resist 12:3903\u201310. Available from: https:\/\/www.dovepress.com\/antimicrobial-resistance-implications-and-costs-peer-reviewed-fulltext-article-IDR","DOI":"10.2147\/IDR.S234610"},{"key":"5103_CR2","doi-asserted-by":"crossref","unstructured":"de Moraes-Pinto MI, Ferrarini MAG (2020) Opportunistic infections in pediatrics: when to suspect and how to approach. Elsevier Editora Ltda [cited 2021 Feb 10]. Jornal de Pediatria 96:47\u201357. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/31790645\/","DOI":"10.1016\/j.jped.2019.09.008"},{"key":"5103_CR3","doi-asserted-by":"publisher","unstructured":"Downes KJ, Hahn A, Wiles J et al (2013) Dose optimisation of antibiotics in children: application of pharmacokinetics\/pharmacodynamics in paediatrics. Int J Antimicrob Agents. Available from: https:\/\/doi.org\/10.1016\/j.ijantimicag.2013.11.006","DOI":"10.1016\/j.ijantimicag.2013.11.006"},{"issue":"58","key":"5103_CR4","first-page":"S108","volume":"2018","author":"J Le","year":"2017","unstructured":"Le J, Bradley JS (2017) Optimizing antibiotic drug therapy in pediatrics: current state and future needs. J Clin Pharmacol 2018(58):S108\u2013S122","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"5103_CR5","first-page":"64","volume":"33","author":"E Novak","year":"2007","unstructured":"Novak E, Allen PJ (2007) Prescribing medications in pediatrics: concerns regarding FDA approval and pharmacokinetics. Pediatr Nurs 33(1):64\u201370","journal-title":"Pediatr Nurs"},{"key":"5103_CR6","unstructured":"Food and Drug Administration (2022) Population Pharmacokinetics. Guidance for Industry. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/population-pharmacokinetics"},{"key":"5103_CR7","doi-asserted-by":"publisher","unstructured":"Rashed AN, Jackson C, Gastine S et al (2019) Pediatric pharmacokinetics of the antibiotics in the access and watch groups of the 2019 WHO model list of essential medicines for children: a systematic review. Expert Rev Clin Pharmacol 12(12):1099\u2013106. Available from: https:\/\/doi.org\/10.1080\/17512433.2019.1693257","DOI":"10.1080\/17512433.2019.1693257"},{"key":"5103_CR8","doi-asserted-by":"publisher","unstructured":"Hartman SJF, Br\u00fcggemann RJ, Orri\u00ebns L et al (2020) Pharmacokinetics and target attainment of antibiotics in critically Ill children: a systematic review of current literature. Vol. 59, Clinical Pharmacokinetics. Springer International Publishing pp. 173\u2013205. Available from: https:\/\/doi.org\/10.1007\/s40262-019-00813-w","DOI":"10.1007\/s40262-019-00813-w"},{"issue":"12","key":"5103_CR9","doi-asserted-by":"publisher","first-page":"3330","DOI":"10.1093\/jac\/dkw408","volume":"71","author":"D Reeves","year":"2016","unstructured":"Reeves D, Lovering A, Thomson A (2016) Therapeutic drug monitoring in the past 40 years of the Journal of Antimicrobial Chemotherapy. J Antimicrob Chemother 71(12):3330\u20133332","journal-title":"J Antimicrob Chemother"},{"key":"5103_CR10","doi-asserted-by":"publisher","unstructured":"Ates HC, Roberts JA, Lipman J et al (2020) On-site therapeutic drug monitoring. Trends Biotechnol. Available from: https:\/\/doi.org\/10.1016\/j.tibtech.2020.03.001","DOI":"10.1016\/j.tibtech.2020.03.001"},{"key":"5103_CR11","doi-asserted-by":"crossref","unstructured":"Imani S, Buscher H, Marriott D et al (2017) Too much of a good thing: a retrospective study of \u03b2-lactam concentration-toxicity relationships. J Antimicrob Chemother [cited 2021 May 20] 72(10):2891\u20137. Available from: https:\/\/academic.oup.com\/jac\/article\/72\/10\/2891\/3952632","DOI":"10.1093\/jac\/dkx209"},{"key":"5103_CR12","doi-asserted-by":"crossref","unstructured":"Roger C, Louart B (2021) Beta-lactams toxicity in the intensive care unit: an underestimated collateral damage? Microorganism 9(7):1505. Available from: https:\/\/www.mdpi.com\/2076-2607\/9\/7\/1505\/htm","DOI":"10.3390\/microorganisms9071505"},{"key":"5103_CR13","doi-asserted-by":"crossref","unstructured":"Schwartz GJ, Haycock GB, Edelmann CM et al (1976) A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 58(2):259\u201363. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/951142\/","DOI":"10.1542\/peds.58.2.259"},{"key":"5103_CR14","doi-asserted-by":"publisher","unstructured":"Smith MJ, Gonzalez D, Goldman JL et al (2017) Pharmacokinetics of clindamycin in obese and nonobese children. Antimicrob Agents Chemother 61(4). Available from: https:\/\/doi.org\/10.1128\/AAC.02014-16","DOI":"10.1128\/AAC.02014-16"},{"key":"5103_CR15","doi-asserted-by":"publisher","unstructured":"Gonzalez D, Melloni C, Yogev R et al (2014) Use of opportunistic clinical data and a population pharmacokinetic model to support dosing of clindamycin for premature infants to adolescents. Clin Pharmacol Ther 96(4):429\u201337. Available from: https:\/\/doi.org\/10.1038\/clpt.2014.134","DOI":"10.1038\/clpt.2014.134"},{"key":"5103_CR16","doi-asserted-by":"crossref","unstructured":"Autmizguine J, Guptill JT, Cohen-Wolkowiez M et al (2014) Pharmacokinetics and pharmacodynamics of antifungals in children: clinical implications. Vol. 74, Drugs. Springer International Publishing, p. 891\u2013909","DOI":"10.1007\/s40265-014-0227-3"},{"issue":"11","key":"5103_CR17","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1093\/cid\/ciu657","volume":"59","author":"KCM Van Der Elst","year":"2014","unstructured":"Van Der Elst KCM, Pereboom M, Van Den Heuvel ER et al (2014) Insufficient fluconazole exposure in pediatric cancer patients and the need for therapeutic drug monitoring in critically Ill children. Clin Infect Dis 59(11):1527\u20131533","journal-title":"Clin Infect Dis"},{"issue":"1","key":"5103_CR18","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/j.1875-9114.1995.tb04331.x","volume":"15","author":"RE Seay","year":"1995","unstructured":"Seay RE, Larson TA, Toscano JP et al (1995) Pharmacokinetics of fluconazole in immune-compromised children with leukemia or other hematologic disease. Pharmacother J Hum Pharmacol Drug Ther 15(1):52\u201358","journal-title":"Pharmacother J Hum Pharmacol Drug Ther"},{"issue":"96","key":"5103_CR19","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ijid.2020.03.054","volume":"1","author":"L Dou","year":"2020","unstructured":"Dou L, Meng D, Dong Y et al (2020) Dosage regimen and toxicity risk assessment of linezolid in sepsis patients. Int J Infect Dis 1(96):105\u2013111","journal-title":"Int J Infect Dis"},{"issue":"8","key":"5103_CR20","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.jsps.2019.09.002","volume":"27","author":"A Alsultan","year":"2019","unstructured":"Alsultan A (2019) Determining therapeutic trough ranges for linezolid. Saudi Pharm J 27(8):1061\u20131063","journal-title":"Saudi Pharm J"},{"key":"5103_CR21","doi-asserted-by":"crossref","unstructured":"Boak LM, Rayner CR, Grayson ML et al (2014) Clinical population pharmacokinetics and toxicodynamics of linezolid. Antimicrob Agents Chemother 58(4):2334\u201343. Available from: https:\/\/journals.asm.org\/journal\/aac","DOI":"10.1128\/AAC.01885-13"},{"key":"5103_CR22","doi-asserted-by":"publisher","unstructured":"Garcia-Prats AJ, Schaaf HS, Draper HR et al (2019) Pharmacokinetics, optimal dosing, and safety of linezolid in children with multidrug-resistant tuberculosis: combined data from two prospective observational studies. PLOS Med 16(4):e1002789. Available from: https:\/\/doi.org\/10.1371\/journal.pmed.1002789","DOI":"10.1371\/journal.pmed.1002789"},{"key":"5103_CR23","doi-asserted-by":"publisher","unstructured":"Dhaese S, Van Vooren S, Boelens J et al (2020) Therapeutic drug monitoring of \u03b2-lactam antibiotics in the ICUm, pp. 1155\u201364. Available from: https:\/\/doi.org\/10.1080\/14787210.2020.1788387","DOI":"10.1080\/14787210.2020.1788387"},{"key":"5103_CR24","doi-asserted-by":"publisher","unstructured":"Hassan HE, Ivaturi V, Gobburu J et al (2020) Dosage regimens for meropenem in children with pseudomonas infections do not meet serum concentration targets. Clin Transl Sci 13(2):301\u20138. Available from: https:\/\/doi.org\/10.1111\/cts.12710","DOI":"10.1111\/cts.12710"},{"issue":"4","key":"5103_CR25","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1093\/jpids\/piy040","volume":"8","author":"J Child","year":"2019","unstructured":"Child J, Chen X, Mistry RD et al (2019) Pharmacokinetic and pharmacodynamic properties of metronidazole in pediatric patients with acute appendicitis: a prospective study. J Pediatric Infect Dis Soc 8(4):297\u2013302","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"4","key":"5103_CR26","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1128\/AAC.06071-11","volume":"56","author":"M Cohen-Wolkowiez","year":"2012","unstructured":"Cohen-Wolkowiez M, Ouellet D, Smith PB et al (2012) Population pharmacokinetics of metronidazole evaluated using scavenged samples from preterm infants. Antimicrob Agents Chemother 56(4):1828\u20131837","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"5103_CR27","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.diagmicrobio.2006.06.013","volume":"55","author":"KA Sprandel","year":"2006","unstructured":"Sprandel KA, Drusano GL, Hecht DW et al (2006) Population pharmacokinetic modeling and Monte Carlo simulation of varying doses of intravenous metronidazole. Diagn Microbiol Infect Dis 55(4):303\u2013309","journal-title":"Diagn Microbiol Infect Dis"},{"key":"5103_CR28","doi-asserted-by":"crossref","unstructured":"Thibault C, Lavigne J, Litalien C et al (2019) Population pharmacokinetics and safety of piperacillin-tazobactam extended infusions in infants and children. Antimicrob Agents Chemother 63(11):1-12. Available from: https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01260-19","DOI":"10.1128\/AAC.01260-19"},{"key":"5103_CR29","doi-asserted-by":"publisher","unstructured":"B\u00e9ranger A, Benaboud S, Urien S et al (2018) Piperacillin population pharmacokinetics and dosing regimen optimization in critically Ill children with normal and augmented renal clearance. Clin Pharmacokinet 58(2):223\u201333. Available from: https:\/\/doi.org\/10.1007\/s40262-018-0682-1","DOI":"10.1007\/s40262-018-0682-1"},{"issue":"10","key":"5103_CR30","doi-asserted-by":"publisher","first-page":"2984","DOI":"10.1093\/jac\/dkz270","volume":"74","author":"A Thorsted","year":"2019","unstructured":"Thorsted A, Kristoffersson AN, Maarbjerg SF et al (2019) Population pharmacokinetics of piperacillin in febrile children receiving cancer chemotherapy: the impact of body weight and target on an optimal dosing regimen. J Antimicrob Chemother 74(10):2984\u20132993","journal-title":"J Antimicrob Chemother"},{"key":"5103_CR31","doi-asserted-by":"publisher","unstructured":"Zhang T, Cheng H, Pan Z et al (2020) Desired vancomycin trough concentration to achieve an AUC0\u201324\/MIC \u2265400 in Chinese children with complicated infectious diseases. Basic Clin Pharmacol Toxicol 126(1):75\u201385. Available from: https:\/\/doi.org\/10.1111\/bcpt.13303","DOI":"10.1111\/bcpt.13303"},{"key":"5103_CR32","doi-asserted-by":"crossref","unstructured":"Le J, Ny P, Capparelli E et al (2015) Pharmacodynamic characteristics of nephrotoxicity associated with vancomycin use in children. J Pediatric Infect Dis Soc 4(4):e109\u201316. Available from: https:\/\/academic.oup.com\/jpids\/article\/4\/4\/e109\/2580148","DOI":"10.1093\/jpids\/piu110"},{"key":"5103_CR33","doi-asserted-by":"publisher","unstructured":"Smit C, Goulooze SC, Br\u00fcggemann RJM et al (2021) Dosing recommendations for vancomycin in children and adolescents with varying levels of obesity and renal dysfunction: a population pharmacokinetic study in 1892 children aged 1\u201318 years. AAPS J 23(3):1\u201310. Available from:\u00a0https:\/\/doi.org\/10.1208\/s12248-021-00577-x","DOI":"10.1208\/s12248-021-00577-x"},{"key":"5103_CR34","doi-asserted-by":"crossref","unstructured":"Alsultan A, Abouelkheir M, Alqahtani S et al (2018) Optimizing vancomycin monitoring in pediatric patients. Pediatr Infect Dis J 37(9):880\u20135. Available from: https:\/\/journals.lww.com\/pidj\/Fulltext\/2018\/09000\/Optimizing_Vancomycin_Monitoring_in_Pediatric.8.aspx","DOI":"10.1097\/INF.0000000000001943"},{"key":"5103_CR35","doi-asserted-by":"crossref","unstructured":"Santos Buelga D, Del Mar Fernandez De Gatta M, Herrera EV et al (2005) Population pharmacokinetic analysis of vancomycin in patients with hematological malignancies. Antimicrob Agents Chemother 49(12):4934\u201341. Available from: https:\/\/journals.asm.org\/journal\/aac","DOI":"10.1128\/AAC.49.12.4934-4941.2005"},{"key":"5103_CR36","unstructured":"Food and Drug Administration (2018) Bioanalytical Method Validation. Guidance for Industry. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/bioanalytical-method-validation-guidance-industry"},{"key":"5103_CR37","doi-asserted-by":"crossref","unstructured":"Patel BM, Paratz J, See NC et al (2012) Therapeutic drug monitoring of beta-lactam antibiotics in burns patients-a one-year prospective study. Ther Drug Monit 34(2):160\u20134. Available from: https:\/\/journals.lww.com\/drug-monitoring\/Fulltext\/2012\/04000\/Therapeutic_Drug_Monitoring_of_Beta_Lactam.8.aspx","DOI":"10.1097\/FTD.0b013e31824981a6"},{"issue":"5","key":"5103_CR38","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s40262-017-0576-7","volume":"57","author":"AR Maharaj","year":"2018","unstructured":"Maharaj AR, Gonzalez D, Cohen-Wolkowiez M et al (2018) Improving pediatric protein binding estimates: an evaluation of \u03b11-acid glycoprotein maturation in healthy and infected subjects HHS Public Access. Clin Pharmacokinet 57(5):577\u2013589","journal-title":"Clin Pharmacokinet"},{"key":"5103_CR39","doi-asserted-by":"publisher","unstructured":"Kays MB, White RL, Gatti G et al (1992) Ex vivo protein binding of clindamycin in sera with normal and elevated \u03b11-acid glycoprotein concentrations. Pharmacother J Hum Pharmacol Drug Ther 12(1):50\u20135. Available from: https:\/\/doi.org\/10.1002\/j.1875-9114.1992.tb02671.x","DOI":"10.1002\/j.1875-9114.1992.tb02671.x"},{"key":"5103_CR40","unstructured":"EUCAST. MIC Breakpoints. [cited 14 Apr 2021]. Available from: https:\/\/mic.eucast.org"},{"issue":"6","key":"5103_CR41","doi-asserted-by":"publisher","DOI":"10.1097\/pq9.0000000000000236","volume":"4","author":"B Burns","year":"2019","unstructured":"Burns B, Hartenstein M, Lin A et al (2019) Optimizing time to antibiotic administration in children with possible febrile neutropenia through quality improvement methodologies. Pediatr Qual Saf 4(6):e236","journal-title":"Pediatr Qual Saf"},{"key":"5103_CR42","doi-asserted-by":"publisher","unstructured":"White L, Ybarra M (2017) Neutropenic fever. Hematol Oncol Clin North Am 31(6):981\u201393. Available from: https:\/\/doi.org\/10.1016\/j.hoc.2017.08.004","DOI":"10.1016\/j.hoc.2017.08.004"},{"key":"5103_CR43","doi-asserted-by":"crossref","unstructured":"Cohen-Wolkowiez M, Benjamin DK (2014) Fluconazole therapeutic drug monitoring in children with cancer: not today. Vol. 59, Clinical Infectious Diseases. Oxford University Press; p. 1534\u20136","DOI":"10.1093\/cid\/ciu661"},{"key":"5103_CR44","doi-asserted-by":"crossref","unstructured":"Stockmann C, Constance JE, Roberts JK et al (2014) Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications. Vol. 53, Clinical Pharmacokinetics. Springer International Publishing; p. 429\u201354","DOI":"10.1007\/s40262-014-0139-0"},{"key":"5103_CR45","doi-asserted-by":"crossref","unstructured":"Costenaro P, Minotti C, Cuppini E et al (2020) Optimizing antibiotic treatment strategies for neonates and children: does implementing extended or prolonged infusion provide any advantage? Vol. 9, Antibiotics. MDPI AG; p. 1\u201320","DOI":"10.3390\/antibiotics9060329"},{"issue":"108","key":"5103_CR46","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.ijid.2021.05.044","volume":"1","author":"T Chongcharoenyanon","year":"2021","unstructured":"Chongcharoenyanon T, Wacharachaisurapol N, Anugulruengkitt S et al (2021) Comparison of piperacillin plasma concentrations in a prospective randomised trial of extended infusion versus intermittent bolus of piperacillin\/tazobactam in paediatric patients. Int J Infect Dis 1(108):102\u2013108","journal-title":"Int J Infect Dis"},{"issue":"3","key":"5103_CR47","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1111\/jcpt.13369","volume":"6","author":"NA Steffens","year":"2021","unstructured":"Steffens NA, Zimmermann ES, Nichelle SM et al (2021) Meropenem use and therapeutic drug monitoring in clinical practice: a literature review. J Clin Pharm Ther 6(3):610\u2013621.\u00a0Available from:\u00a0https:\/\/doi.org\/10.1111\/jcpt.13369","journal-title":"J Clin Pharm Ther"},{"key":"5103_CR48","doi-asserted-by":"crossref","unstructured":"Germovsek E, Lutsar I, Kipper K et al (2018) Plasma and CSF pharmacokinetics of meropenem in neonates and young infants: results from the NeoMero studies. J Antimicrob Chemother 73(7):1908\u201316. Available from: https:\/\/academic.oup.com\/jac\/article\/73\/7\/1908\/4978317","DOI":"10.1093\/jac\/dky128"},{"key":"5103_CR49","unstructured":"Huttner A, Harbarth S, Hope WW et al (2015) Therapeutic drug monitoring of the \u03b2-lactam antibiotics: what is the evidence and which patients should we be using it for? J Antimicrob Chemother 70(12):3178\u201383. Available from: https:\/\/academic.oup.com\/jac\/article\/70\/12\/3178\/2363621"},{"key":"5103_CR50","doi-asserted-by":"crossref","unstructured":"Scharf C, Paal M, Schroeder I et al (2020) Therapeutic drug monitoring of meropenem and piperacillin in critical illness\u2014experience and recommendations from one year in routine clinical practice. Antibiotics 9(3):131. Available from: www.mdpi.com\/journal\/antibiotics","DOI":"10.3390\/antibiotics9030131"},{"key":"5103_CR51","doi-asserted-by":"crossref","unstructured":"Guilhaumou R, Marsot A, Dupouey J et al (2016) Pediatric patients with solid or hematological tumor disease: vancomycin population pharmacokinetics and dosage optimization. Ther Drug Monit 38(5):559\u201366. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/27631462\/","DOI":"10.1097\/FTD.0000000000000318"},{"key":"5103_CR52","doi-asserted-by":"crossref","unstructured":"Zhao W, Zhang D, Fakhoury M et al (2014) Population pharmacokinetics and dosing optimization of vancomycin in children with malignant hematological disease. Antimicrob Agents Chemother 58(6):3191\u20139. Available from: https:\/\/journals.asm.org\/journal\/aac","DOI":"10.1128\/AAC.02564-13"},{"key":"5103_CR53","doi-asserted-by":"crossref","unstructured":"Marsot A, Gallais F, Galambrun C et al (2018) Vancomycin in pediatric patients with solid or hematological malignant disease: predictive performance of a population pharmacokinetic model and new optimized dosing regimens. Paediatr Drug 20(4):375\u201381. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/29736878\/","DOI":"10.1007\/s40272-018-0295-z"}],"container-title":["European Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-023-05103-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00431-023-05103-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-023-05103-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,16]],"date-time":"2023-12-16T23:01:48Z","timestamp":1702767708000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00431-023-05103-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,12]]},"references-count":53,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["5103"],"URL":"https:\/\/doi.org\/10.1007\/s00431-023-05103-z","relation":{},"ISSN":["1432-1076"],"issn-type":[{"value":"1432-1076","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,12]]},"assertion":[{"value":"16 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was carried out in line with ethical principles of the Declaration of Helsinki. Approval was granted by the Research and Ethics Committee of <i>Hospital Central \u201cDr. Ignacio Morones Prieto<\/i>,<i>\u201d<\/i> SLP, M\u00e9xico (Registration number 69-21; August 26<sup>th<\/sup>, 2021).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from patients\u2019 parents, and informed assent was obtained from patients over 12\u00a0years of age.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}